Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Specific tetracycline Recombinant Mouse Monoclonal Antibody (5B11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Specific tetracycline Antibody (MA566313) in SDS-PAGE
SDS-PAGE characterization of Specific tetracycline under reducing conditions. Lane M: Protein marker (kDa); Lane TC: Purified Specific tetracycline Recombinant Monoclonal (Product # MA566313). Specific tetracycline showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-419.
产品信息
MA566313
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
5B11
抗原
Conjugate of TC hapten and KLH.
偶联物
形式
Liquid
浓度
1.6 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Tetracycline biosimilars are derived from tetracycline antibiotics, which are known for their diverse structures and broad-spectrum antibacterial activity. These antibiotics have been in clinical use for over seven decades, with continuous contributions to human health. The biosynthesis of tetracycline involves complex pathways that produce various natural products with remarkable bioactivities. Tetracycline biosimilars, such as eravacycline and omadacycline, have unique chemical structures that help them retain activity against bacteria with tetracycline-specific resistance mechanisms. These biosimilars are effective against a wide range of bacterial infections, although they lack activity against Pseudomonas species. The development of tetracycline biosimilars focuses on enhancing their efficacy and overcoming resistance, ensuring their continued relevance in medical treatments.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
